LIVN - LivaNova PLC Stock Price, Fair Value and News

53.61USD+0.16 (+0.30%)Market Closed

Market Summary

USD53.61+0.16

Market Closed

0.30%

LIVN Stock Price

View Fullscreen

LIVN RSI Chart

LIVN Valuation

Market Cap

2.9B

Price/Earnings (Trailing)

-91.39

Price/Sales (Trailing)

2.45

EV/EBITDA

-82.36

Price/Free Cashflow

95.36

LIVN Price/Sales (Trailing)

LIVN Profitability

EBT Margin

-10.56%

Return on Equity

-2.6%

Return on Assets

-1.29%

Free Cashflow Yield

1.05%

LIVN Fundamentals

LIVN Revenue

Revenue (TTM)

1.2B

Rev. Growth (Yr)

11.96%

Rev. Growth (Qtr)

-4.91%

LIVN Earnings

Earnings (TTM)

-31.8M

Earnings Growth (Yr)

-669.1%

Earnings Growth (Qtr)

-356.7%

Breaking Down LIVN Revenue

Last 7 days

1.3%

Last 30 days

-1.6%

Last 90 days

-3.5%

Trailing 12 Months

-6.5%

How does LIVN drawdown profile look like?

LIVN Financial Health

Current Ratio

3.17

Debt/Equity

0.5

Debt/Cashflow

0.11

LIVN Investor Care

Shares Dilution (1Y)

0.71%

Diluted EPS (TTM)

-0.6

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.2B	0	0	0
2023	1.0B	1.1B	1.1B	1.2B
2022	1.0B	1.0B	1.0B	1.0B
2021	939.4M	1.0B	1.0B	1.0B
2020	1.1B	980.8M	952.3M	934.2M
2019	1.1B	1.1B	1.1B	1.1B
2018	1.0B	1.1B	1.1B	1.1B
2017	782.5M	799.8M	983.6M	1.0B
2016	640.9M	811.4M	982.4M	782.7M
2015	253.7M	255.8M	263.4M	294.7M
2014	275.1M	282.0M	285.1M	288.5M
2013	0	254.3M	261.2M	268.2M

Get all data in R, Python etc through our Historical Stock Data APIs

About LivaNova PLC

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. It also engages in research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.

CEO	Mr. William A. Kozy
WEBSITE	livanova.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	2900

LivaNova PLC Frequently Asked Questions

What is the ticker symbol for LivaNova PLC? What does LIVN stand for in stocks?

LIVN is the stock ticker symbol of LivaNova PLC. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of LivaNova PLC (LIVN)?

As of Fri Jul 26 2024, market cap of LivaNova PLC is 2.9 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LIVN stock?

You can check LIVN's fair value in chart for subscribers.

Is LivaNova PLC a good stock to buy?

The fair value guage provides a quick view whether LIVN is over valued or under valued. Whether LivaNova PLC is cheap or expensive depends on the assumptions which impact LivaNova PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LIVN.

What is LivaNova PLC's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, LIVN's PE ratio (Price to Earnings) is -91.39 and Price to Sales (PS) ratio is 2.45. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LIVN PE ratio will change depending on the future growth rate expectations of investors.